Gluteal Injection Site: Ventrogluteal vs. Dorsogluteal

The gluteal region is the most commonly used area for intramuscular (IM) injections worldwide, but the term covers two distinct sites that differ substantially in safety, comfort, and reliability. The dorsogluteal site, located on the upper outer buttock, has been the traditional default for decades. The ventrogluteal site, located on the hip, is now recommended by most nursing guidelines as the safer alternative. Despite that shift in official guidance, real-world practice has been slow to catch up, and the choice between sites has consequences that go well beyond convenience.

Where Exactly Are These Sites?

The dorsogluteal site sits in the upper outer quadrant of the buttock, over the gluteus maximus and gluteus medius muscles. Clinicians historically locate it by mentally dividing the buttock into four quadrants and aiming for the upper outer one, which keeps the needle away from the sciatic nerve running through the lower portions. The ventrogluteal site is on the side of the hip, in a triangular area formed by the iliac crest (the top ridge of the hip bone), the bony point at the front of the hip, and the greater trochanter of the femur (the bony bump you can feel at the side of your upper thigh).¹ This triangular zone overlies the gluteus medius and gluteus minimus, which are thinner muscles but sit farther from major nerves and blood vessels.

The practical difference matters. The dorsogluteal site is easier to find by eyeball, which is one reason it became standard. But it sits closer to the sciatic nerve and the superior gluteal artery, two structures you very much do not want a needle to hit. The ventrogluteal site requires slightly more anatomical knowledge to locate properly, involving specific hand placement over the hip landmarks, but it offers a much larger margin of safety.

How Often Do Gluteal Injections Actually Reach the Muscle?

This is where the standard narrative about gluteal injections starts to break down. Multiple imaging studies have found that a startling share of injections intended for gluteal muscle tissue never reach it. One CT-based study of 50 patients found that only about a third of intended IM injections actually landed in muscle, with the remaining two-thirds depositing medication into the subcutaneous fat layer instead.² The failure was far worse in women: only about 8% of female patients received a true IM injection, compared with roughly 56% of men. Other imaging studies have reported success rates ranging from about 32% to 58%, depending on the population and assessment method.³

The reason is straightforward: the buttock carries a thick layer of subcutaneous fat, and standard-length needles often are not long enough to pass through it. When a medication designed for muscle absorption ends up in fat tissue instead, it absorbs more slowly and less predictably. For time-sensitive medications like pain relievers and antibiotics, this can mean delayed relief. For long-acting depot medications used in psychiatry, it can mean unreliable drug levels over weeks or months.

Body Size, Needle Length, and Why One Size Does Not Fit All

The thickness of subcutaneous fat over the gluteal region varies enormously from person to person, and body mass index is the strongest single predictor. A systematic review of dorsogluteal injection depth found that women with a BMI of 25 or above generally need needles longer than the standard 38 mm (1.5 inches) to reach muscle, while men typically only need longer needles at a BMI of 35 and above.⁴ The sex difference reflects where the body preferentially deposits fat: women tend to accumulate more subcutaneous tissue over the buttocks than men at the same overall weight.

The ventrogluteal site has somewhat thinner fat coverage than the dorsogluteal site, but it is not immune to this problem. One study found that the expected failure rate of IM delivery at the ventrogluteal site using a standard 1.5-inch needle was about 71% in women with a BMI over 30 and about 60% in men with a BMI over 35.⁵ Those are remarkably high failure rates for a routine medical procedure. BMI correlated strongly with subcutaneous fat thickness at the ventrogluteal site for both sexes, meaning a clinician can use BMI as a practical guide for choosing needle length.

Research comparing the two sites and both sexes suggests that a 32-mm needle generally succeeds at the ventrogluteal site for all males and normal-weight females, while a 38-mm needle works for nearly all females at the ventrogluteal site and for virtually all patients at the dorsogluteal site, at least among those without high BMI.⁶ In practice, many clinics still reach for a standard 1.5-inch needle regardless of the patient’s build, which helps explain why imaging studies find so many misplaced injections.

Why the Ventrogluteal Site Is Considered Safer

A systematic review and meta-analysis comparing the two gluteal sites across multiple studies found that the ventrogluteal site was associated with meaningfully less pain, less bleeding, and smaller hematomas at both 48 and 72 hours after injection.⁷ The ventrogluteal area has fewer major blood vessels running through it, which accounts for the lower bleeding and hematoma risk. It also has fewer sensory nerve endings near the injection zone, which contributes to lower reported pain.

Beyond comfort, the most important safety advantage is distance from the sciatic nerve. Sciatic nerve injury from a misplaced gluteal injection is rare but devastating, capable of causing permanent foot drop, chronic pain, or partial paralysis of the lower leg. A review of Supreme Court decisions in Turkey related to injection-induced sciatic nerve injuries found that gluteal injections accounted for about 79% of the cases, with nurses performing about 60% of the injections involved.⁸ Most of these injuries involved the dorsogluteal site. The ventrogluteal site lies well away from the sciatic nerve’s path, making this complication essentially impossible when the site is correctly identified.

Complications Beyond Nerve Injury

Sciatic nerve damage gets the most attention, but gluteal injections carry other risks that are worth knowing about, especially if you receive them regularly.

Nicolau syndrome is a rare but severe complication in which the injected medication causes local blood vessel spasm or blockage, leading to tissue death at and around the injection site. It presents as sudden, intense pain during or immediately after injection, followed by discoloration of the skin that can progress to full-thickness necrosis and ulceration. Case reports have linked it to gluteal injections of non-steroidal anti-inflammatory drugs, among other medications.⁹ One contributing factor is the injection landing in fat rather than muscle, particularly in patients with thick subcutaneous layers and when standard-length needles are used.¹⁰

Vascular complications can also occur when the needle damages the superior gluteal artery. Incorrect injection technique can cause bleeding from this artery, leading to a deep hematoma. If such a hematoma becomes infected, it can progress to a deep abscess and eventually systemic infection.¹¹ These cascading complications are uncommon, but they underscore why site selection and injection technique are not just academic concerns.

The Z-Track Technique

The Z-track method is a specific injection technique where the clinician pulls the skin and subcutaneous tissue to one side before inserting the needle, holds it displaced during the injection, and then releases it after withdrawing the needle. The displaced tissue layers slide back into their original position, creating a zigzag path that seals the injection tract and prevents medication from leaking back along the needle track to the skin surface.

Studies on this technique have found it reduces drug leakage from the injection site compared to standard technique. One trial found that using the Z-track method for intramuscular diclofenac reduced leakage, though it did not significantly reduce injection pain.¹² A randomized controlled trial in patients receiving intramuscular magnesium sulfate found that the Z-track group experienced less pain at certain injection points, less drug leakage, and less gluteal inflammation on both sides compared to the standard injection method.¹³ The Z-track technique is now widely recommended for all gluteal IM injections, not just for irritating medications, though it is especially important for drugs known to stain or damage subcutaneous tissue.

Gluteal vs. Deltoid for Drug Absorption

The gluteal muscles have slightly lower blood flow at rest compared to the deltoid muscle in the upper arm, a difference of roughly 19%.¹⁴ Lower blood flow means drugs injected into the gluteal site absorb into the bloodstream somewhat more slowly and reach lower peak concentrations. For many routine medications, this difference is clinically insignificant. But for drugs where rapid initial absorption matters, it can influence how clinicians choose between sites.

This plays out clearly with long-acting injectable antipsychotics, which are among the most common medications given by gluteal injection. Studies on paliperidone palmitate found that drug exposure was about 20-30% higher after deltoid injection compared to gluteal injection during the initial dosing period, with higher and more variable peak concentrations in the deltoid.¹⁵ That is why prescribing guidelines for some long-acting antipsychotics specify that the first doses should go into the deltoid to build up blood levels quickly, with the option to switch to gluteal for ongoing maintenance injections. At steady state, the difference between the two sites narrows considerably.¹⁶

For other long-acting formulations, the difference between sites is minimal enough that they can be used interchangeably. Studies on aripiprazole lauroxil found that total drug exposure was similar between deltoid and gluteal administration, even though peak concentrations were slightly higher with deltoid injection.¹⁷ A study of the nanocrystal dispersion formulation of the same drug confirmed similar exposure and safety profiles between the two sites.¹⁸ Local tolerability at the injection site tends to be slightly better with gluteal injections, likely because the larger muscle mass and thicker overlying tissue cushion the injection.

Gluteal Injections in Children

The gluteal site poses special concerns in pediatric patients. Young children have relatively less gluteal muscle mass than adults, and the sciatic nerve occupies a proportionally larger area of the buttock. A review in Pediatrics noted that sciatic nerve injury is the most frequently reported serious complication of gluteal injections in children.¹⁹ For this reason, most pediatric guidelines recommend the vastus lateralis (the outer thigh) as the primary IM injection site for infants and young children, reserving gluteal sites for older children and adolescents who have developed enough muscle mass. The thigh carries its own risk profile, with muscle contracture being the most common serious complication at that site, but the risk-benefit calculation favors it over gluteal injection in small children.

Why Most Nurses Still Use the Dorsogluteal Site

Despite years of published guidelines favoring the ventrogluteal site, clinical practice has been remarkably resistant to change. A study examining nurses’ preferences found that the majority did not use the ventrogluteal site, citing a lack of knowledge about how to locate it and concern that they might injure patients by using an unfamiliar landmark.²⁰ The dorsogluteal site is what most nurses learned in school, practiced on mannequins, and used thousands of times in their careers. Switching to a different landmark system feels risky, even when the evidence says the opposite.

Educational interventions can shift this. One convergent care research study found that after training, nurses who had previously preferred the dorsogluteal site unanimously switched their preference to the ventrogluteal site and could correctly describe the anatomical landmarks needed to find it.²¹ The barrier is not that the ventrogluteal site is difficult to learn. It is that many training programs and clinical environments have not yet prioritized making the switch. If you are a patient who receives frequent gluteal injections, it is reasonable to ask your clinician which site they are using and why.

Ultrasound and the Future of Injection Site Verification

One emerging approach to the problem of misplaced injections is using portable ultrasound to visualize the tissue layers before or during injection. Ultrasound can show the skin, subcutaneous fat, muscle membrane, and muscle itself in real time, allowing a clinician to see exactly how deep the muscle lies and whether the chosen needle will reach it.²² Imaging studies using B-mode ultrasound have also revealed that the distance from skin surface to muscle can differ between a patient’s right and left buttock, adding another layer of unpredictability that visual assessment alone cannot account for.²³

Ultrasound-guided injection is already standard for certain procedures like joint injections and nerve blocks, but it is not yet practical for routine IM injections given the time and equipment involved. As handheld ultrasound devices become cheaper and more widely available, this could change. For now, the practical takeaway is that BMI-based needle selection and use of the ventrogluteal site together offer the best odds of a successful injection without imaging.

Legal Consequences of Injection Errors

The legal analysis of sciatic nerve injuries from injections in Turkey provides a sobering look at what happens when gluteal injections go wrong. Among the court cases reviewed, negligent bodily injury was the most common charge, and about a third of cases also involved claims for monetary compensation. Most injuries occurred during injections given for postoperative pain relief or antibiotic treatment. Nurses were the providers in about 60% of cases, with individual health professionals named as defendants in roughly two-thirds of lawsuits and hospitals named in about a quarter.²⁴ These numbers reflect a system where the dorsogluteal site remains dominant and where injection training may not consistently emphasize landmarking technique. They also illustrate that injection-site errors are treated as preventable harm in the legal system, not as acceptable risks of routine care.